

## Ensituximab

Cat. No.:	HY-P99362
CAS No.:	1092658-06-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer <sup>[1][2]</sup> .
<b>In Vitro</b>	Ensituximab (NPC-1C) is a chimeric IgG1 monoclonal antibody that promotes antibody-dependent cellular cytotoxicity after binding its target, a tumor-specific variant of MUC5AC, an antigen that is specifically expressed by colorectal (CRC) and pancreatic cancers <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564.

[2]. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA